PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis

PARP1 has been shown to regulate EBV latency. However, the therapeutic effect of PARP1 inhibitors on EBV+ lymphomagenesis has not yet been explored. Here, we show that PARPi BMN-673 has a potent anti-tumor effect on EBV-driven LCL in a mouse xenograft model. We found that PARP1 inhibition induces a...

Descripción completa

Detalles Bibliográficos
Autores principales: Napoletani, Giorgia, Soldan, Samantha S., Kannan, Toshitha, Preston-Alp, Sarah, Vogel, Peter, Maestri, Davide, Caruso, Lisa Beatrice, Kossenkov, Andrew, Sobotka, Asher, Lieberman, Paul M., Tempera, Italo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350008/
https://www.ncbi.nlm.nih.gov/pubmed/37461649
http://dx.doi.org/10.1101/2023.07.05.547847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350008/
https://www.ncbi.nlm.nih.gov/pubmed/37461649
http://dx.doi.org/10.1101/2023.07.05.547847

Ejemplares similares